| 2026-03-06 |
详情>>
内部人交易：
Pennell Sandra股份增加5533.00股
|
| 2026-02-26 |
详情>>
股本变动：
变动后总股本3474.62万股
|
| 2026-02-26 |
详情>>
业绩披露：
2025年年报每股收益0.08美元,归母净利润270.00万美元,同比去年增长110.23%
|
| 2026-02-26 |
财报披露：
美东时间 2026-02-26 盘前发布财报
|
| 2025-11-04 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.13美元,归母净利润459.60万美元,同比去年增长119.99%
|
| 2025-08-06 |
详情>>
业绩披露：
2025年中报每股收益0.11美元,归母净利润376.60万美元,同比去年增长115.15%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益0.03美元,归母净利润106.90万美元,同比去年增长109.62%
|
| 2025-04-01 |
股东大会：
将于2025-05-15召开股东大会
会议内容 ▼▲
- 1.To elect Gerard Michel and Gilad Aharon as a Class I directors for a term expiring at the 2028 annual meeting of the Company’s stockholders and until their successors are elected and qualified, or, if sooner, until the director’s death, resignation, retirement, disqualification or removal;
2.To approve an amendment of the Company’s 2020 Omnibus Equity Incentive Plan to increase by 2,200,000 the number of shares of common stock, $0.01 par value per share (“Common Stock”) available thereunder;
3.To approve an amendment of the Company’s 2021 Employee Stock Purchase Plan to increase by 300,000 the number of shares of Common Stock available thereunder;
4.To ratify the selection, by the Audit Committee of our Board of Directors, of CBIZ CPAs (“CBIZ CPAs”), Inc. as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025;
5.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement (“Proxy Statement”);
6.To transact such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-0.93美元,归母净利润-2638.6万美元,同比去年增长44.66%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.84美元,归母净利润-2298.8万美元,同比去年增长37.09%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益-0.93美元,归母净利润-2485.2万美元,同比去年增长-53.39%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.45美元,归母净利润-1111.1万美元,同比去年增长-23.46%
|
| 2024-04-12 |
股东大会：
将于2024-05-23召开股东大会
会议内容 ▼▲
- 1.To elect Steven Salamon as a Class III director for a term expiring at the 2027 annual meeting of the Company’s stockholders and until their successors are elected and qualified;
2.To approve an amendment of the Company’s 2020 Omnibus Equity Incentive Plan to increase by 2,000,000 the number of shares of common stock, $0.01 par value per share (“Common Stock”) available thereunder;
3.To ratify the selection, by the Audit Committee of our Board of Directors, of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024;
4.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement (“Proxy Statement”);
5.To transact such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2024-03-26 |
详情>>
业绩披露：
2023年年报每股收益-2.94美元,归母净利润-4767.8万美元,同比去年增长-30.6%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.61美元,归母净利润-3654.2万美元,同比去年增长-30.34%
|
| 2023-05-01 |
股东大会：
将于2023-06-12召开股东大会
会议内容 ▼▲
- 1.To elect Elizabeth Czerepak and John R. Sylvester as Class II directors for a term expiring at the 2026 annual meeting of the Company’s stockholders and until their successors are elected and qualified;
2.To approve an amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock, $0.01 par value per share (the “Common Stock”) from 40,000,000 shares to 80,000,000;
3.To approve an amendment of the Company’s 2020 Omnibus Equity Incentive Plan to increase by 2,650,000 the number of shares of Common Stock available under thereunder;
4.To approve the potential issuance in excess of 19.99% of the Company’s outstanding Common Stock upon the conversion of the Company’s Series F-1 Convertible Preferred Stock, par value $0.01 per share (the “Series F-1 Preferred Stock”), Series F-2 Convertible Preferred Stock, par value $0.01 per share (the “Series F-2 Preferred Stock”), Series F-3 Convertible Preferred Stock, par value $0.01 per share (the “Series F-3 Preferred Stock”) and Series F-4 Convertible Preferred Stock, par value $0.01 per share (the “Series F-4 Preferred Stock” and, together with the Series F-1 Preferred Stock, the Series F-2 Preferred Stock and the Series F-3 Preferred Stock, the “Series F Preferred Stock”) at less than the “minimum price” under Nasdaq Listing Rule 5635(d), and which may be deemed a “change of control” under Nasdaq Listing Rule 5635, pursuant to the terms of the Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Voting Preferred Stock governing the Series F Preferred Stock;
5.To ratify the selection, by the Audit Committee of our Board of Directors, of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023;
6.To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement (“Proxy Statement”);
7.To recommend, on a non-binding advisory basis, the frequency of holding an advisory vote on executive compensation;
8.To transact such other business as may properly come before the Annual Meeting or any adjournments thereof.
|
| 2022-04-04 |
股东大会：
将于2022-05-04召开股东大会
会议内容 ▼▲
- 1.to elect two Class I nominees as Class I directors for a term expiring at the 2025 annual meeting of the Company’s stockholders and until their successors are elected and qualified;
2.to approve the adoption of the Company’s 2021 Employee Stock Purchase Plan;
3.to ratify the selection, by the Audit Committee of our Board of Directors, of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2022;
4.to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
5.to transact such other business as may properly come before the 2022 Annual Meeting or any adjournments thereof.
|
| 2021-12-02 |
复牌提示：
2021-12-02 09:32:51 停牌，复牌日期 2021-12-02 09:37:51
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-07 |
股东大会：
将于2021-05-06召开股东大会
会议内容 ▼▲
- 1.to elect two Class III nominees as Class III directors for a term expiring at the 2024 annual meeting of the Company’s stockholders and until their successors are elected and qualified;
2.to approve an amendment of the Company’s 2020 Omnibus Equity Incentive Plan to increase by 1,800,000 shares the number of shares available under the 2020 Omnibus Equity Incentive Plan;
3.to ratify the selection, by the Audit Committee of our Board of Directors, of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2021;
4.to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the proxy statement;
5.to transact such other business as may properly come before the 2021 Annual Meeting or any adjournments thereof.
|
| 2020-11-02 |
股东大会：
将于2020-11-23召开股东大会
会议内容 ▼▲
- 1.to elect the two Class II nominees named in the accompanying proxy statement as Class II directors for a term expiring at the 2023 Annual Meeting of Stockholders and until their successors are elected and qualified;
2.to approve an amendment to the Company’s amended and restated certificate of incorporation to reduce the total number of authorized shares of the Company’s common stock, $0.01 par value, from 1,000,000,000 shares to 40,000,000 shares;
3.to approve the Company’s 2020 Omnibus Equity Incentive Plan;
4.to ratify the selection, by the Audit Committee of our Board of Directors, of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2020;
5.to approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement;
6.to transact such other business as may properly come before the 2020 Annual Meeting or any adjournment or postponement thereof.
|
| 2017-06-06 |
股东大会：
将于2017-06-16召开股东大会
会议内容 ▼▲
- 1. To vote on the election of Harold S. Koplewicz, M.D as a Class II director, to serve until the 2020 annual meeting of stockholders and until his successor is duly elected and qualified;
2. To cast a non-binding, advisory vote on the compensation of our named executive officers (“say-on-pay”);
3. To cast a non-binding, advisory vote on the frequency of “say-on-pay”;
4. To ratify the appointment by our Audit Committee of Grant Thornton, LLP as Delcath’s independent registered public accounting firm for the fiscal year ending December 31, 2017
5. To approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock, such split to combine a whole number of outstanding shares of our common stock in a range of not less than fifty shares and not more than five hundred shares, into one share of common stock in the discretion of the Board of Directors, and to grant authorization to the Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing;
6. To transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.meeting.
|
| 2016-07-21 |
详情>>
拆分方案：
每16.0000合并分成1.0000股
|
| 2016-06-21 |
股东大会：
将于2016-07-19召开股东大会
会议内容 ▼▲
- 1. To vote on the election of William D. Rueckert and Marco Taglietti as Class I directors, each to serve until the 2019 annual meeting of stockholders and until his successor is duly elected and qualified.
2. To cast a non-binding, advisory vote on the compensation of our named executive officers (“say-on-pay”).
3. To ratify the appointment by our Audit Committee of Grant Thornton, LLP as Delcath’s independent registered public accounting firm for the fiscal year ending December 31, 2016.
4. To adopt an amendment to Delcath’s 2009 Stock Incentive Plan, effective upon approval by our stockholders at the Annual Meeting, (i) to increase the number of our shares of common stock with respect to which grants may be made under the plan by 1,700,000 shares to 3,206,250 shares, (ii) eliminate provisions that include shares withheld from plan participants by the Company in connection with the cashless exercise of stock options, settlement of Stock Appreciation Rights or in satisfaction of tax withholding obligations as available for reissuance under the plan, (iii) establish a minimum one-year vesting period for grants under the plan, (iv) re-approve the plan, extending its termination date to the day preceding the tenth anniversary of the Annual Meeting unless the plan is further re-approved prior to such date and (v) make certain other technical or administrative changes;
5. To approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of our common stock at one of six ratios of 1-for-10, 1-for-12, 1-for-14, 1-for-16, 1-for-18 or 1-for-20, in the discretion of the Board of Directors, and to grant authorization to the Board of Directors to determine, in its sole discretion, whether to implement the reverse stock split, as well as its specific timing;
6. To approve, for purposes of complying with NASDAQ Listing Rule 5635(d), the issuance of shares of our common stock underlying senior secured convertible notes and related Series C Warrants issued by us pursuant to the terms of that certain Securities Purchase Agreement, dated June 6, 2016 (the “Securities Purchase Agreement”), between the Company and the investors named therein, without giving effect to the exchange cap in such senior secured convertible notes in an amount that may be equal to or exceed 20% of our common stock outstanding before the issuance of such senior secured convertible notes and related Series C Warrants (the “NASDAQ 20% Issuance Proposal”);
7. To approve an amendment to our amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 170,000,000 to 500,000,000;
8. To transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|
| 2015-04-29 |
股东大会：
将于2015-06-10召开股东大会
会议内容 ▼▲
- (1)To vote on the election of Roger G. Stoll, Ph.D. and Dennis H. Langer, M.D., J.D. as Class III directors, each to serve until the 2018 annual meeting of stockholders and until his successor is duly elected and qualified.
(2)To cast a non-binding, advisory vote on the compensation of our named executive officers (“say-on-pay”).
(3)To ratify the appointment by our Audit Committee of Grant Thornton, LLP as Delcath’s independent registered public accounting firm for the fiscal year ending December 31, 2015.
(4)To adopt an amendment to Delcath’s 2009 Stock Incentive Plan to increase the total number of shares of Delcath common stock reserved for issuance under the plan by 1,100,000 shares.
(5)To transact such other business as may properly come before the meeting or any adjournment or postponement of the meeting.
|